Sandra Bohn Thomsen

Sandra Bohn Thomsen

Auto-generated profile, based on publicly available information

Sandra Bohn Thomsen

Gastro Unit, Copenhagen University Hospital Hvidovre, Kettegårds Alle 30, Hvidovre 2600 , Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
RERahma Elmahdi
Rahma Elmahdi
CLCamilla E. Lemser
Camilla E. Lemser
STSandra B. Thomsen
Sandra B. Thomsen
KAKristine H. Allin
Kristine H. Allin
MAManasi Agrawal
Manasi Agrawal
TJTine Jess
Tine Jess
The hallmarks of inflammatory bowel disease (IBD), a chronic immune-mediated inflammatory disease of the gastrointestinal tract, are progressive intestinal injury and systemic inflammation, which can lead to complications such as cancer. Inflammatory bowel disease is associated with an increased risk of several types of cancer, including colon, small bowel, and upper gastrointestinal tract cancers.1 In contrast to the risk of cancer among adult patients with IBD, the risk of cancer among patients with pediatric-onset IBD is not well investigated, to our knowledge. Pediatric patients with IBD may have longer durations of exposure to the chronic inflammatory state and thereby a higher risk of cancer.2 Furthermore, among children, the incidence of IBD and the risk of cancer have increased in recent years.3,4

5 March 2022 in eClinicalMedicine
Verified
Journal Article
Open access
MKMarianne Kiszka-Kanowitz
Marianne Kiszka-Kanowitz
KTKlaus Theede
Klaus Theede
STSandra Bohn Thomsen
Sandra Bohn Thomsen
Jacob Tveiten BjerrumJacob Tveiten Bjerrum
Jacob Tveiten Bjerrum
JBJørn Brynskov
Jørn Brynskov
AMAnette Mertz-Nielsen
Anette Mertz-Nielsen
Retrospective studies suggest that for patients with ulcerative colitis (UC) combination therapy with low-dose azathioprine and allopurinol (L-AZA/ALLO) may result in higher remission rates than monotherapy with azathioprine (AZA). We prospectively investigated the effects of these drugs for remission in patients with moderate-to-severe UC. Open-label, unblinded, randomised, controlled, investigator-initiated, multicentre study conducted at eight hospital sites in Denmark. Adult patients with established UC, who were steroid dependent/refractory, thiopurine naïve, had a normal thiopurine methyltransferase, and achieved remission with steroids or infliximab were eligible for inclusion. Patients were randomly assigned by the investigators (1:1) to 52 weeks of treatment with once daily oral AZA (median dose 50 mg) combined with ALLO 100 mg versus AZA monotherapy (median dose 200 mg), using a computer-generated randomisation list with blocks of six. The trial was open without masking. All randomised patients who received at least one dose of study drug were included in primary and safety analyses (intention to treat population). The primary outcome was steroid and infliximab free remission after 52 weeks, defined as a Mayo Score of ≤1 and no rectal bleeding. The trial is completed and is registered in ClinicalTrials.gov (ClinicalTrials.gov NCT03101800). Between January 9, 2017 and February 10, 2021, 47 patients were randomised to l-AZA/ALLO and 42 to AZA and received at least one dose of the study drug. After 52 weeks, 20 of 47 (43%) patients in the l-AZA/ALLO group and nine of 42 (21%) patients in the AZA group achieved remission (odds ratio 2·54 [95% CI 1·00 to 6.78, p < 0·048]). Fourteen patients (30%) in the l-AZA/ALLO group and 16 (38%) in the AZA group were withdrawn from the study due to adverse events. This study suggests that after one year l-AZA/ALLO therapy may be associated with a beneficial effect on steroid- and infliximab-free clinical remission in patients with moderate-to-severe UC and should be considered as first line therapy. Funding for AAUC was provided by The Capital Region of Denmark (Regionernes Medicinpulje (6062/16)).

3 February 2018 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
JBJohan Burisch
Johan Burisch
JGJavier P Gisbert
Javier P Gisbert
BSBritta Siegmund
Britta Siegmund
DBDominik Bettenworth
Dominik Bettenworth
STSandra Bohn Thomsen
Sandra Bohn Thomsen
ELEbbe Langholz
Ebbe Langholz
The ‘United Registries for Clinical Assessment and Research’ [UR-CARE] database is an initiative of the European Crohn’s and Colitis Organisation [ECCO] to facilitate daily patient care and research studies in inflammatory bowel disease [IBD]. Herein, we sought to validate the database by using fictional case histories of patients with IBD that were to be entered by observers of varying experience in IBD. Nineteen observers entered five patient case histories into the database. After 6 weeks, all observers entered the same case histories again. For each case history, 20 key variables were selected to calculate the accuracy for each observer. We assumed that the database was such that ≥ 90% of the entered data would be correct. The overall proportion of correctly entered data was calculated using a beta-binomial regression model to account for inter-observer variation and compared to the expected level of validity. Re-test reliability was assessed using McNemar’s test. For all case histories, the overall proportion of correctly entered items and their confidence intervals included the target of 90% (Case 1: 92% [88–94%]; Case 2: 87% [83–91%]; Case 3: 93% [90–95%]; Case 4: 97% [94–99%]; Case 5: 91% [87–93%]). These numbers did not differ significantly from those found 6 weeks later [NcNemar’s test p > 0.05]. The UR-CARE database appears to be feasible, valid and reliable as a tool and easy to use regardless of prior user experience and level of clinical IBD experience. UR-CARE has the potential to enhance future European collaborations regarding clinical research in IBD.

1 February 2020 in United European Gastroenterology Journal
Verified
Journal Article
Open access
PDF file
STSandra Bohn Thomsen
Sandra Bohn Thomsen
KAKristine Højgaard Allin
Kristine Højgaard Allin
JBJohan Burisch
Johan Burisch
CJCamilla Bjørn Jensen
Camilla Bjørn Jensen
SHSusanne Hansen
Susanne Hansen
TJTine Jess
Tine Jess
Background: Thiopurine and allopurinol in combination are associated with clinical remission in inflammatory bowel diseases but their influence on subsequent outcomes is unclear. We compared outcomes during exposure to both thiopurines and allopurinol versus thiopurines alone.Methods: We established a nationwide cohort of patients with inflammatory bowel diseases exposed to thiopurines ± allopurinol during 1999–2014, using registry data. Patients were followed until hospitalization, surgery, anti‐TNFα, or death (as a primary composite outcome). We used Poisson regression analyses to calculate incidence rate ratios overall and stratified by calendar period (assuming the combined exposure was unintended before 2009).Results: A total of 10,367 patients with inflammatory bowel diseases (Crohn’s disease, n = 5484; ulcerative colitis, n = 4883) received thiopurines. Of these, 217 (2.1%) also received allopurinol. During 24,714 person years of follow‐up, we observed 40 outcomes among thiopurine‐allopurinol‐exposed patients, and 4745 outcomes among those who were thiopurine exposed; incidence rate ratio, 1.26 (95% confidence interval, 0.92–1.73). The incidence rate ratios decreased over time: 4.88 (95% confidence interval 2.53–9.45) for 1999–2003, 2.19 (95% confidence interval, 1.17–4.09) for 2004–2008 and 0.80 (95% confidence interval, 0.52–1.23) for 2009–2014.Conclusion: Our nationwide inflammatory bowel disease cohort study shows that concomitant thiopurine‐allopurinol is as safe to use as thiopurines alone, with a tendency towards a positive effect on clinical outcomes in recent calendar periods when combined use was intended.

25 January 2022 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
STSandra Bohn Thomsen
Sandra Bohn Thomsen
RURyan C. Ungaro
Ryan C. Ungaro
KAKristine H. Allin
Kristine H. Allin
RERahma Elmahdi
Rahma Elmahdi
GPGry Poulsen
Gry Poulsen
TJTine Jess
Tine Jess